The Pill That Kills Quietly: What Every Brother Should Know About Chemical Abortion
By Ray Ross (Respect Life Team)
Most Americans who oppose abortion picture a clinic. A waiting room, a procedure, a protest sign on the sidewalk outside. But that picture is out of date. Today, most abortions in America don't happen in a clinic at all. They happen in a bathroom, a dorm room, a bedroom — set in motion by two small pills that arrive in an unmarked envelope, no doctor in the room, sometimes no doctor even on the phone.
This is chemical abortion, and it is now the dominant method of ending a pregnancy in the United States. Understanding how it works — and how it is being fought over in Congress, in statehouses, and at the Supreme Court — is essential for anyone who wants to defend the unborn and the women targeted by this industry.
How the Pills Work
Chemical abortion is a two-drug regimen: mifepristone followed by misoprostol.
Mifepristone, first developed in France and often called by its old name RU-486, is an anti-progesterone drug. Progesterone is the hormone that sustains a pregnancy — it maintains the uterine lining so the developing child can stay implanted and nourished. Mifepristone binds to progesterone receptors and blocks the hormone from doing its job. Deprived of that support, the uterine lining begins to break down, cutting off the child's supply line.
Misoprostol, taken 24 to 48 hours later, finishes the job. It triggers strong uterine contractions that expel the child's body, along with the placenta and lining, from the womb. The process is often compared to a miscarriage — because, medically speaking, that is exactly what it is designed to induce. Women typically pass their child at home: in the toilet, the shower, or wherever they happen to be when the contractions take hold.
The FDA has approved this regimen only through 10 weeks of pregnancy, though it is frequently used off-label later, and a growing number of providers now offer a misoprostol-only protocol — usually because it doesn't require verifying a mifepristone prescription, though studies suggest it causes more pain, nausea, and bleeding than the standard two-drug regimen.
What the Risks Actually Are
Advocates for the drug — including the FDA itself, in public messaging — have long described serious complications as exceedingly rare, citing a rate below half of one percent. That figure traces largely to clinical trials from around the time of the drug's original approval in 2000.
Newer, real-world data tells a more troubling story. In April 2025, the Ethics and Public Policy Center (EPPC) released the largest insurance-claims study of the abortion pill to date, analyzing 865,727 mifepristone abortions between 2017 and 2023. The researchers, Jamie Bryan Hall and Ryan T. Anderson, found that nearly 11 percent of women suffered sepsis, infection, hemorrhaging, or another serious adverse event within 45 days of taking the drug — a rate they calculate as at least 22 times higher than the FDA's own labeled figure. A companion EPPC analysis using the same dataset found that roughly one in twenty women needed a second abortion attempt within 45 days because the first one failed to work.
The FDA's own post-marketing safety records add another grim data point: as of the end of 2024, the agency had logged 36 reports of patient deaths associated with mifepristone since its approval in 2000, including women who died from undiagnosed ectopic pregnancies and from sepsis. The agency is careful to note it cannot attribute every death to the drug with full certainty, given gaps in follow-up records — but the FDA has also confirmed it is now conducting its own dedicated safety study of mifepristone, at the direction of Health Secretary Robert F. Kennedy Jr.
It's worth being honest that these figures are contested. Groups that support legal abortion dispute the EPPC's methodology, and one medical commentator has placed the real complication rate closer to 1 in 200. That gap — whether it's 1 in 200 or 1 in 10 — is itself the scandal: a quarter-century after approval, there is no longer scientific consensus on how dangerous this drug actually is, in large part because the systems meant to track its harms have been loosened rather than strengthened.
What is not contested is that mifepristone is contraindicated for women with an undiagnosed ectopic pregnancy, since it can allow a ruptured tube to go undetected until it becomes a life-threatening emergency. Under the current mail-order system, there is often no ultrasound, no blood test, and no in-person exam to catch that risk before the pills are ever taken.
This is a two-part article. Next month in Part 2 I’ll cover Senate Hearings as well as actions by the Courts.